Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
Solid Biosciences Inc. Common Stock
SLDB
Mkt Cap
$594.5M
Volume
1.10M
Next Earnings
November 2nd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
SLDB
SL
Solid Biosciences Inc. Common Stock
SLDB
News
·
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
Mkt Cap
$615.5M
Volume
1.10M
Next Earnings
November 2nd
Chart
Financials
Earnings
News
About
Insider
Filings
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.
GlobeNewswire Inc. · May 26, 2026
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
U.S. Department of Health and Human Services added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, which is expected to accelerate early detection and improve patient outcomes.
GlobeNewswire Inc. · Dec 16, 2025
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia. The therapy aims to restore frataxin protein levels and address neurologic, cardiac, and systemic disease manifestations.
GlobeNewswire Inc. · Dec 1, 2025
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Solid Biosciences has signed a non-exclusive worldwide license agreement with Andelyn Biosciences to provide access to its proprietary AAV-SLB101 gene therapy capsid, expanding collaborative efforts to over 30 agreements.
GlobeNewswire Inc. · Nov 17, 2025
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences will participate in two healthcare investor conferences in November and December 2025, featuring presentations by its President/CEO and Chief Medical Officer, with live webcasts available.
GlobeNewswire Inc. · Nov 11, 2025
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences awarded 55,450 restricted stock units to four newly hired employees, with vesting over four years, under their 2024 Inducement Stock Incentive Plan.
GlobeNewswire Inc. · Aug 1, 2025
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight
The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options.
GlobeNewswire Inc. · Jun 5, 2025
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences, a life sciences company developing precision genetic medicines, announced its participation in two upcoming investor conferences, where the company's leadership will discuss its pipeline of gene therapy candidates for neuromuscular and cardiac diseases.
GlobeNewswire Inc. · Nov 26, 2024
Rocket Lab stock downgraded by Morgan Stanley due to revised growth outlook By Investing.com - Investing.com
JPMorgan has upgraded Solid Biosciences' stock from Neutral to Overweight, citing the company's promising gene therapy pipeline and the favorable regulatory environment for its products.
Investing.com · Jul 15, 2024
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
GlobeNewswire Inc. · Jul 1, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
SL
SLDB
Solid Biosciences Inc. Common Stock
Buy
Sell
Market
Limit
Soon
SLDB
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any SLDB yet.
Related Tickers
Earnings